Cowen and Company recently initiated coverage, with an “Outpeform” rating and a target of $3, representing the first time a major Wall Street firm has provided research on an OTC name in the cannabis sector. Cannabis Stocks Heat Up in Front of Legalization Votes

thumbnail courtesy of newcannabisventures.com